The Ameriprise Financial Inc. Reached $1,543,000 position of Radius Health Inc. (RDUS)

The Ameriprise Financial Inc. Reached $1,543,000 position  of Radius Health Inc. (RDUS)

Ameriprise Financial Inc. increased its position in Radius Health Inc. (NASDAQ:RDUS) by 138.0% during the second quarter, Holdings Channel reports. The institutional investor owned 41,981 shares of the biopharmaceutical company’s stock after buying an additional 24,345 shares during the period. Ameriprise Financial Inc. owned about 0.10% of Radius Health worth $1,543,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of RDUS. Teachers Advisors Inc. increased its position in shares of Radius Health by 1.9% in the first quarter. Teachers Advisors Inc. now owns 50,805 shares of the biopharmaceutical company’s stock worth $1,597,000 after buying an additional 926 shares in the last quarter. BlackRock Fund Advisors increased its position in shares of Radius Health by 2.5% in the first quarter. BlackRock Fund Advisors now owns 1,367,137 shares of the biopharmaceutical company’s stock worth $42,983,000 after buying an additional 33,421 shares in the last quarter. BlackRock Institutional Trust Company N.A. increased its position in shares of Radius Health by 0.5% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 807,600 shares of the biopharmaceutical company’s stock worth $25,391,000 after buying an additional 3,792 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Radius Health by 79.7% in the first quarter. JPMorgan Chase & Co. now owns 147,112 shares of the biopharmaceutical company’s stock worth $4,626,000 after buying an additional 65,259 shares in the last quarter. Finally, State Street Corp increased its position in shares of Radius Health by 39.9% in the first quarter. State Street Corp now owns 1,588,379 shares of the biopharmaceutical company’s stock worth $49,938,000 after buying an additional 453,302 shares in the last quarter. Institutional investors and hedge funds own 99.98% of the company’s stock.

Radius Health Inc. (NASDAQ:RDUS) traded up 0.14% on Friday, hitting $43.09. 982,404 shares of the company’s stock were exchanged. The company’s 50-day moving average price is $52.67 and its 200-day moving average price is $44.52. The company’s market cap is $1.86 billion. Radius Health Inc. has a 12-month low of $24.75 and a 12-month high of $75.50.

Radius Health (NASDAQ:RDUS) last announced its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.95) by $0.06. During the same quarter last year, the business posted ($0.61) EPS. Analysts forecast that Radius Health Inc. will post ($3.97) earnings per share for the current year.

RDUS has been the subject of several research reports. Jefferies Group reaffirmed a “hold” rating and issued a $46.00 price target on shares of Radius Health in a research report on Tuesday, September 20th. Canaccord Genuity set a $85.00 price target on shares of Radius Health and gave the stock a “buy” rating in a research report on Monday, September 19th. HC Wainwright upped their price target on shares of Radius Health from $55.00 to $71.00 and gave the stock a “buy” rating in a research report on Wednesday, September 21st. Cowen and Company reaffirmed a “buy” rating on shares of Radius Health in a research report on Wednesday, September 28th. Finally, JPMorgan Chase & Co. reaffirmed a “buy” rating and issued a $70.00 price target on shares of Radius Health in a research report on Friday, August 5th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Radius Health has an average rating of “Buy” and an average target price of $63.51.

About Radius Health

Radius Health, Inc is a biopharmaceutical company focused on developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Its product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase III development for use in the reduction of fracture risk in postmenopausal women with osteoporosis.

Related posts

Leave a Comment